TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01497327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSI-352938
Description: PSI-352938 300mg once daily (QD) for seven days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSI-352938
Description: PSI-352938 300mg once daily (QD) for seven days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSI-352938
Description: PSI-352938 300mg once daily (QD) for seven days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSI-7977
Description: PSI-7977 400mg QD for seven days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSI-7977
Description: PSI-7977 400mg QD for seven days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSI-7977
Description: PSI-7977 400mg QD for seven days
Study: NCT00904306

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: placebo oral tablet taken once per day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: chromium picolinate
Description: 1000 ug/day chromium picolinate for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: chromium picolinate
Description: 600 ug/day chromium picolinate
Study: NCT04871074

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UCB-J
Description: PET imaging with UCB-J

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UCB-J
Description: PET imaging with UCB-J

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UCB-J
Description: PET imaging with UCB-J

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI Scan
Description: MRI exams will be performed using a 3T MRI scanner, scan duration is typically 60 minutes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI Scan
Description: MRI exams will be performed using a 3T MRI scanner, scan duration is typically 60 minutes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI Scan
Description: MRI exams will be performed using a 3T MRI scanner, scan duration is typically 60 minutes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PET Scan
Description: PET imaging may be collected using either a PET scanner or a PET/Computed Tomography (CT) scanner, a PET scan will be initiated with the injection of radiotracer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PET Scan
Description: PET imaging may be collected using either a PET scanner or a PET/Computed Tomography (CT) scanner, a PET scan will be initiated with the injection of radiotracer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PET Scan
Description: PET imaging may be collected using either a PET scanner or a PET/Computed Tomography (CT) scanner, a PET scan will be initiated with the injection of radiotracer
Study: NCT05462470

Intervention type: PROCEDURE
Intervention: Repeat Liver Surgery
Description: repeat liver surgery included not only hepatectomy, but also ablative treatment, including radiofrequency ablation (RFA) and microwave ablation (MWA)

Intervention type: PROCEDURE
Intervention: Non-Repeat Liver Surgery
Description: Systemic palliative chemotherapy
Study: NCT01845064

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03008538

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MPM(Mineralized plasmatic matrix).
Description: Preparation of sticky bone graft by addition of growth factors obtained from patient's vebous blood.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous Bone Graft
Description: Socket preservation using autogenous bone graft for preservation of bone width and height for future implant insertion.
Study: NCT00560326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus Ointment 0.03%
Description: Once or twice daily topical application
Study: NCT01259830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arcoxia®120 mg
Description: Arcoxia® over encapsulated 120 mg; Perioperatively 6 days 1 tablet (Arcoxia® 120 mg) for oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: P Tablet White Lichtenstein
Description: P Tablet White Lichtenstein over encapsulated; Perioperatively 6 days 1 tablet for oral use
Study: NCT01174667

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Specific massage for fascial release
Description: Patient will receive a 3 minute massage to reduce restrictions in the lumbodorsal fascia.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Quiet non-instructed rest for 3 minutes
Description: Patient will lay quietly without any instructions on how to relax.
Study: NCT02243137

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetylsalicylic acid
Description: Administration: one dose of Acetylsalicylic Acid (300mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prasugrel
Description: Administration: one loading dose (60mg)
Study: NCT02465112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: In111-Pentetréotide

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: simple monitoring without active therapy
Study: NCT03364790

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PLIF
Description: Randomly include the 30 participants diagnosed LSS and knee arthritis or limited by knee extension greater than 10 °who need to be operated and then performed PLIF or PLF; include anothr ones of 30 need to be with the implementation of TKA;and another group with the same diagnosis will be underwent both of surgeries in one stage.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PLIF
Description: Randomly include the 30 participants diagnosed LSS and knee arthritis or limited by knee extension greater than 10 °who need to be operated and then performed PLIF or PLF; include anothr ones of 30 need to be with the implementation of TKA;and another group with the same diagnosis will be underwent both of surgeries in one stage.
Study: NCT04301388

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transvaginal ultrasound
Description: Transvaginal ultrasound to measure cervical length if persist regular uterine contraction

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound
Description: Transvaginal ultrasound to measure cervical length if persist regular uterine contraction
Study: NCT02896608

Intervention type: DEVICE
Intervention: measure of neuronal excitability

Intervention type: DEVICE
Intervention: measure of neuronal excitability

Intervention type: DEVICE
Intervention: measure of neuronal excitability
Study: NCT00599677

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Subjects are treated five days a week continuously, and for four weeks.They are treated 30min every time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Subjects are treated five days a week continuously, and for four weeks.They are treated 30min every time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Subjects are treated five days a week continuously, and for four weeks.They are treated 30min every time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Subjects are treated five days a week continuously, and for four weeks.They are treated 30min every time.
Study: NCT03364790

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TKA
Description: Randomly include the 30 participants diagnosed LSS and knee arthritis or limited by knee extension greater than 10 °who need to be operated and then performed PLIF or PLF; include anothr ones of 30 need to be with the implementation of TKA;and another group with the same diagnosis will be underwent both of surgeries in one stage.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TKA
Description: Randomly include the 30 participants diagnosed LSS and knee arthritis or limited by knee extension greater than 10 °who need to be operated and then performed PLIF or PLF; include anothr ones of 30 need to be with the implementation of TKA;and another group with the same diagnosis will be underwent both of surgeries in one stage.
Study: NCT00424801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lercanidipine
Description: Individual titration, max. dose 20 mg OD for 8 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Individual titration, max. dose 160 mg OD for 8 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorandil
Description: Individual titration, max. dose 20 mg BD for 8 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin
Description: Individual titration, max. dose 4 mg OD for 8 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxonidin
Description: Possible add-on therapy in case target blood pressure can not be reached with a combination of the other drugs in the Vasodilatory arm. Individual titration, max. dose 0,2 mg OD for 8 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pindolol
Description: Possible add-on therapy in case target blood pressure can not be reached with a combination of the other drugs in the Vasodilatory arm. Individual titration, max. dose 10 mg OD for 8 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiloride, hydrochlorothiazide
Description: Possible add-on therapy in case target blood pressure can not be reached with a combination of the other drugs in the Vasodilatory arm. Individual titration, max. dose 1 tbl. OD for 8 months
Study: NCT03391310

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Honey (medicated)
Description: Honey (medicated) dressing will be used in the experimental group
Study: NCT04093414

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Select Secure pacing lead
Description: A Select Secure pacing lead is placed in the bundle of His or Left bundle branch area based upon randomization
Study: NCT02243137

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prasugrel
Description: Administration: one loading dose (60mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lysine acetylsalicylate
Description: Administration: one dose (450mg iv)
Study: NCT03275857

Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: Weekly IV
Study: NCT03253744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL
Description: Participants will receive 2-(3-{1-carboxy-5-\[(6-18F-fluoro-pyridine-3-carbonyl)-amino\]-pentyl}-ureido)-pentanedioic acid at baseline and 6 months after radiation. The maximum amount of injected active drug will be less than 4.02 micrograms. The target administered activity will be 6-6.5 mCi.
Study: NCT04209348

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention
Description: Motivational interviewing techniques helped participants set reasonable, specific, and achievable individual goals at each session: a duration (i.e., minutes) and frequency (i.e., days of the week) of walking or stepping, and potentially, a step count (i.e., a proxy for intensity). Individual goals often differed from the program goal in an effort to meet the participants 'where they are'.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wellness Education
Description: The following topics were addressed: postpartum contraception, maternal immunizations, infant immunizations, car seat safety and planning for your hospital stay, and safe sleep and skin to skin. No information on PA was provided to the control group (i.e., neither encouragement for PA nor instructions to limit PA).
Study: NCT02344615

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NS-guided infraclavicular block
Description: Patients received a standard single injection infraclavicular block using the lateral sagittal approach of Klaastad. The infraclavicular brachial plexus is identified using an insulated needle connected to a nerve stimulator. Placement of the needle is considered adequate if motor response of radial nerve in the hand or wrist is still present at 0.2 - 0.5mA. Ropivacaine 0.5% 35ml is used.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US-guided infraclavicular block
Description: Infraclavicular block is performed under ultrasound guidance. Linear probe is placed in a parasagittal positon below the clavicle medial to the coracoid process and adjusted to achieve a cross-sectional image of the axillary artery. Using in-plane technique, an 22-gauge insulated needle is advanced caudally and posteriorly to the axillary artery. Subsequently, 35 ml of 0.5% ropivacaine is incrementally injected.
Study: NCT03539354

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Temporary spinal cord stimulation
Description: Percutaneous trial (temporary) electrodes are placed through a 14-gauge needle.The skin is entered at the medial aspect of the pedicle with the Tuohy needle usually angled 30-45° toward the midline for optimal entry into the epidural space at the interlaminar edge 1 or 2 levels of cephalad (usually, Th5-Th6 level). The 14-gauge needle is then passed with the bevel facing up at a 30-45° oblique angle to reach the depth of the midline laminar target.The Tuohy needle is then carefully removed and the operative site is cleaned with chlorhexidine and alcohol. Temporary stimulation is carried out till coronary artery bypass grafting surgery for 3 days, then stimulation turns off during surgery. At the end of coronary artery bypass grafting the temporary stimulation turns on in the intensive care unit and continues for 7 days. After that, the temporary leads will be removed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary artery bypass grafting
Description: Standart coronary artery bypass grafting procedure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting
Description: Standart coronary artery bypass grafting procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B-blockers
Description: Standart b-blocker therapy will be administered in each group for AF prophylactics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B-blockers
Description: Standart b-blocker therapy will be administered in each group for AF prophylactics
Study: NCT00537784

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous platelets
Description: Local injection 10mL, about 2.5 x 10E10 platelets.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: no injection
Study: NCT00074438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Oral or parenteral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Oral or parenteral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Oral or parenteral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Oral or parenteral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Oral or parenteral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Oral or parenteral repeating dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methotrexate
Description: Oral or parenteral repeating dose
Study: NCT00074438

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methotrexate
Description: Oral or parenteral repeating dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methotrexate
Description: Oral or parenteral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Intravenous repeating dose
Study: NCT03253744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL
Description: Participants will receive 2-(3-{1-carboxy-5-\[(6-18F-fluoro-pyridine-3-carbonyl)-amino\]-pentyl}-ureido)-pentanedioic acid at baseline and 6 months after radiation. The maximum amount of injected active drug will be less than 4.02 micrograms. The target administered activity will be 6-6.5 mCi.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL
Description: Participants will receive 2-(3-{1-carboxy-5-\[(6-18F-fluoro-pyridine-3-carbonyl)-amino\]-pentyl}-ureido)-pentanedioic acid at baseline and 6 months after radiation. The maximum amount of injected active drug will be less than 4.02 micrograms. The target administered activity will be 6-6.5 mCi.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Tumor Irradiation
Description: Stereotactic body radiation therapy (SBRT) will be delivered to areas of recurrent prostate cancer identified on imaging and biopsy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Tumor Irradiation
Description: Stereotactic body radiation therapy (SBRT) will be delivered to areas of recurrent prostate cancer identified on imaging and biopsy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prostate + tumor irradiation
Description: Stereotactic body radiation therapy (SBRT) will be delivered to areas of recurrent prostate cancer identified on imaging and biopsy; and a reduced dose will be delivered to the entire prostate.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prostate + tumor irradiation
Description: Stereotactic body radiation therapy (SBRT) will be delivered to areas of recurrent prostate cancer identified on imaging and biopsy; and a reduced dose will be delivered to the entire prostate.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Tumor Irradiation
Description: External beam radiation therapy (EBRT): Participants with locally recurrent prostate cancer after treatment with EBRT. These participants cannot have had permanent brachytherapy as part of their treatment.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Tumor Irradiation
Description: External beam radiation therapy (EBRT): Participants with locally recurrent prostate cancer after treatment with EBRT. These participants cannot have had permanent brachytherapy as part of their treatment.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Tumor Irradiation
Description: External beam radiation therapy (EBRT): Participants with locally recurrent prostate cancer after treatment with EBRT. These participants cannot have had permanent brachytherapy as part of their treatment.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Tumor Irradiation
Description: External beam radiation therapy (EBRT): Participants with locally recurrent prostate cancer after treatment with EBRT. These participants cannot have had permanent brachytherapy as part of their treatment.
Study: NCT02214706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: sirolimus (40 µl) will be applied under occlusion, using van der Bend patch-test chambers (size: 1cm2), and left in situ for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: sirolimus (40 µl) will be applied under occlusion, using van der Bend patch-test chambers (size: 1cm2), and left in situ for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: sirolimus (40 µl) will be applied under occlusion, using van der Bend patch-test chambers (size: 1cm2), and left in situ for 7 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Erbium yag laser
Description: Er:Yag laser ablation of the stratum corneum

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Dye Laser
Study: NCT03097978

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Commercial system
Description: Transhumeral amputees who have had TMR will use a commercially available prosthesis with an elbow,wrist, and a hand with custom electronics and software for both direct and pattern recognition - based control.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Commercial system
Description: Transhumeral amputees who have had TMR will use a commercially available prosthesis with an elbow,wrist, and a hand with custom electronics and software for both direct and pattern recognition - based control.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RIC arm system
Description: Transhumeral amputees who have had TMR will use the RIC arm system prosthesis with an elbow,wrist, and a hand with custom electronics and software for both direct and pattern recognition - based control.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RIC arm system
Description: Transhumeral amputees who have had TMR will use the RIC arm system prosthesis with an elbow,wrist, and a hand with custom electronics and software for both direct and pattern recognition - based control.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct Control
Description: Transhumeral amputees who have had TMR will use either a commercially available prosthesis or the RIC arm system prosthesis with an elbow,wrist, and a hand with custom electronics and software for both direct control.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct Control
Description: Transhumeral amputees who have had TMR will use either a commercially available prosthesis or the RIC arm system prosthesis with an elbow,wrist, and a hand with custom electronics and software for both direct control.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pattern Recognition
Description: Transhumeral amputees who have had TMR will use either a commercially available prosthesis or the RIC arm system prosthesis with an elbow,wrist, and a hand with custom electronics and software for pattern recognition control.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pattern Recognition
Description: Transhumeral amputees who have had TMR will use either a commercially available prosthesis or the RIC arm system prosthesis with an elbow,wrist, and a hand with custom electronics and software for pattern recognition control.
Study: NCT03032809

Intervention type: OTHER
Intervention: Vessel Wall MR imaging
Description: Magnetic resonance images of the intracranial arteries will be acquired using the 3 Tesla MR scanners. Intracranial vessels will be imaged by high resolution vessel wall MR imaging to characterize vessel wall enhancement characteristics and wall thickness.
Study: NCT02668757

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: HeartHab application intervention
Description: The intervention patients will use the HeartHab application on a smartphone. During the study, the patients will use the HeartHab application for 4-6 weeks.
Study: NCT03502200

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUUL
Description: Participants randomized to the JUUL group will receive either tobacco or menthol flavored JUUL with 5% nicotine. Will also receive counseling.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: Nicotine Replacement Therapy consisting of nicotine patches and lozenge along with standard quitline counseling.